Background Routine vaccination of elderly people against pneumococcal diseases is
recommended in many countries. National guidelines differ, recommending either the 23 …

Background Diseases caused by Streptococcus pneumoniae (S. pneumoniae) continue to
cause substantial morbidity and mortality globally. Whilst pneumococcal polysaccharide …

Clin Microbiol Infect 2011; 17 (Suppl. 6): E1–E59 Abstract This document is an update of
Guidelines published in 2005 and now includes scientific publications through to May 2010 …

BACKGROUND Since the 1998 European Respiratory Society (ERS) lower respiratory tract
infection (LRTI) guidelines 1 were published, the evidence on which they were based has …

BACKGROUND: Healthcare reform plans refer to improved quality, but there is little
quantification of potential health benefits of quality care. PURPOSE: This paper aims to …

A bstract Differential cross sections are presented for the prompt and non-prompt production
of the hidden-charm states X (3872) and ψ (2S), in the decay mode J/ψπ+ π−, measured …

OBJECTIVE: This study assessed incidence, aetiology, clinical outcomes and risk factors for
community-acquired pneumonia (CAP) in older adults. METHODS: This was a population …

BACKGROUND: Empyema is a suppurative infection of the pleural space. Without prompt
treatment, it can result in significant hospital stays, more invasive treatments as it …

Two pneumococcal vaccines currently exist and have been recommended for the prevention
of pneumococcal infection in adults 65 years of age and older: the 23-valent polysaccharide …

Background. The benefits of using the 23-valent pneumococcal polysaccharide vaccine
(PPV23) are controversial. This study assessed clinical effectiveness of PPV23 in preventing …